Regulatory press release

Prostatype Genomics appoints Eligen Diagnostica Sociedad Limitada and BioPortugal Quimico Farmacêutica Lda. to distribute the Prostatype ® Prostate gene test in Spain and Portugal

– An important step taken in the commercialization of Prostatype®

In line with the company strategy to pinpoint leading distributors with the ability to work with complex and innovative healthcare solutions, Prostatype Genomics is now entering a collaboration with Eligen Diagnostica and BioPortugal, leading distributors of advanced healthcare solutions in Spain and Portugal. Eligen and BioPortugal will market and distribute the Prostatype® gene test, improving the assessment quality of prostate cancer patients and opening up two new and exciting markets for Prostatype Genomics. This agreement represents a breakthrough in the commercialization efforts for Prostatype®.

Eligen Diagnostica and BioPortugal distribute a range of innovative life science, pharmaceutical and in-vitro diagnostic products that are used in various medical specialities including urology and laboratory medicine. The collaboration starts immediately, and the non-exclusive distribution agreement will be in place at least until end of 2024.

Joaquim Teixeira, CEO of Eligen Diagnostica and BioPortugal comments: “We are happy and proud to be able to represent Prostatype Genomics and Prostatype® in Spain and Portugal. Prostatype® is an innovative, technically advanced product that perfectly matches our strategy in providing leading products bringing real value within the therapeutic field of urology in our markets Spain and Portugal.”

Prostatype Genomics CEO, Fredrik Persson, comments: “We are very happy to have signed distribution agreements with Eligen Diagnostica and BioPortugal. Spain and Portugal are important markets for us and finding the right distribution partner is of the utmost importance. Given the expertise of Eligen and BioPortugal, we are confident that this partnership is a key step in order to establish Prostatype® in the two markets.“

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-08-2021 12:15 CET.